137 related articles for article (PubMed ID: 8742945)
1. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Humberstone AJ; Porter CJ; Charman WN
J Pharm Sci; 1996 May; 85(5):525-9. PubMed ID: 8742945
[TBL] [Abstract][Full Text] [Related]
2. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
Khoo SM; Prankerd RJ; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2002 Mar; 91(3):647-59. PubMed ID: 11920750
[TBL] [Abstract][Full Text] [Related]
3. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
4. Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: Effects on its apparent ionization constant.
Taillardat-Bertschinger A; Perry CS; Galland A; Prankerd RJ; Charman WN
J Pharm Sci; 2003 Nov; 92(11):2217-28. PubMed ID: 14603507
[TBL] [Abstract][Full Text] [Related]
5. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Khoo SM; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.
Khoo SM; Porter JH; Edwards GA; Charman WN
J Pharm Sci; 1998 Dec; 87(12):1538-41. PubMed ID: 10189263
[TBL] [Abstract][Full Text] [Related]
7. Determination of physicochemical properties of halofantrine.
Babalola CP; Adegoke AO; Ogunjinmi MA; Osimosu MO
Afr J Med Med Sci; 2003 Dec; 32(4):357-9. PubMed ID: 15259917
[TBL] [Abstract][Full Text] [Related]
8. The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment.
Khoo SM; Porter CJ; Charman WN
Int J Pharm; 2000 Sep; 205(1-2):65-78. PubMed ID: 11000543
[TBL] [Abstract][Full Text] [Related]
9. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins.
Brocks DR; Wasan KM
J Pharm Sci; 2002 Aug; 91(8):1817-26. PubMed ID: 12115809
[TBL] [Abstract][Full Text] [Related]
10. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
Caliph SM; Trevaskis NL; Charman WN; Porter CJ
J Pharm Sci; 2012 Sep; 101(9):3540-6. PubMed ID: 22623170
[TBL] [Abstract][Full Text] [Related]
11. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation.
Brocks DR; Betageri GV
J Pharm Pharmacol; 2002 Aug; 54(8):1049-53. PubMed ID: 12195818
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of halofantrine.
Karbwang J; Na Bangchang K
Clin Pharmacokinet; 1994 Aug; 27(2):104-19. PubMed ID: 7955774
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
[TBL] [Abstract][Full Text] [Related]
14. Dissolution properties and characterization of halofantrine-2-hydroxypropyl-beta-cyclodextrin binary systems.
Onyeji CO; Omoruyi SI; Oladimeji FA
Pharmazie; 2007 Nov; 62(11):858-63. PubMed ID: 18065103
[TBL] [Abstract][Full Text] [Related]
15. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons.
Brocks DR; Toni JW
Biopharm Drug Dispos; 1999 Apr; 20(3):165-9. PubMed ID: 10211870
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.
du Plessis LH; Govender K; Denti P; Wiesner L
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):68-77. PubMed ID: 26478276
[TBL] [Abstract][Full Text] [Related]
18. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate.
Aideloje SO; Onyeji CO; Ugwu NC
Eur J Pharm Biopharm; 1998 Nov; 46(3):299-303. PubMed ID: 9885302
[TBL] [Abstract][Full Text] [Related]
19. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs.
Stella VJ; Martodihardjo S; Rao VM
J Pharm Sci; 1999 Aug; 88(8):775-9. PubMed ID: 10430541
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vitro evaluation of solid dispersions of halofantrine.
Abdul-Fattah AM; Bhargava HN
Int J Pharm; 2002 Mar; 235(1-2):17-33. PubMed ID: 11879736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
